Last update 29 Aug 2025
Guangxi Fengye Pharmaceutical Investment Co., Ltd.

Guangxi Fengye Pharmaceutical Investment Co., Ltd.

Subsidiary Company|2011|Guangxi Zhuangzu Zizhiqu, China

Overview

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases2
Endocrinology and Metabolic Disease2
Top 5 Drug TypeCount
Small molecule drug4
Top 5 TargetCount
AR(Androgen Receptor)1
NCC x VMAT21
TPO(Thyroid peroxidase)1

Related

4
Drugs associated with Guangxi Fengye Pharmaceutical Investment Co., Ltd.
Benactyzine Methobromide
Target-
Mechanism-
Active Org.
Guangxi Nanning Baihui Pharmaceutical Group Co., LtdGuangxi Nanning Baihui Pharmaceutical Group Co., Ltd
Originator Org.
Guangxi Nanning Baihui Pharmaceutical Group Co., LtdGuangxi Nanning Baihui Pharmaceutical Group Co., Ltd
Active Indication
Duodenal Ulcer [+1]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.-
First Approval Date-
Stanozolol
Target
AR
Mechanism
AR agonists
Active Org.
Guangxi Nanning Baihui Pharmaceutical Group Co., LtdGuangxi Nanning Baihui Pharmaceutical Group Co., Ltd
Originator Org.
H. Lundbeck A/SH. Lundbeck A/S
Active Indication
Hereditary Angioedema [+2]
Inactive Indication
Breast Cancer [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date09 Jan 1962
Hydroflumethiazide/Reserpine
Target
NCC x VMAT2
Mechanism
NCC inhibitors [+1]
Active Org.
Guangxi Nanning Baihui Pharmaceutical Group Co., LtdGuangxi Nanning Baihui Pharmaceutical Group Co., Ltd
Originator Org.
Shire Pharmaceuticals Services Ltd.
Active Indication
Hypertension
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date20 Jun 1960
100 Clinical Results associated with Guangxi Fengye Pharmaceutical Investment Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Guangxi Fengye Pharmaceutical Investment Co., Ltd.
Login to view more data
100 Deals associated with Guangxi Fengye Pharmaceutical Investment Co., Ltd.
Login to view more data
100 Translational Medicine associated with Guangxi Fengye Pharmaceutical Investment Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
4
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Stanozolol
 ( AR )		Hereditary Angioedema
More
Approved
Benactyzine Methobromide
Duodenal Ulcer
More
Approved
Propylthiouracil
 ( TPO )		Hyperthyroidism
More
Approved
Hydroflumethiazide/Reserpine
 ( NCC x VMAT2 )		Hypertension
More
Approved
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free